Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghizadeh, H., Marhold, M., Tomasich, E., Udovica, S., Merchant, A., Krainer, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791446/
https://www.ncbi.nlm.nih.gov/pubmed/31646092
http://dx.doi.org/10.1080/2162402X.2019.1644109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791446/
https://www.ncbi.nlm.nih.gov/pubmed/31646092
http://dx.doi.org/10.1080/2162402X.2019.1644109

Ejemplares similares